KARBE FRANK

Director at Phathom Pharmaceuticals, Inc. · on record since May 21, 2026
Chief Executive Officer at Mountain Crest Acquisition Corp II · on record since Sep 15, 2022
Chief Financial Officer at Cidara Therapeutics, Inc. · on record since Feb 26, 2025
Principal Fin'l & Accounting at Myovant Sciences Ltd. · on record since Oct 26, 2016
Senior VP & CFO at EXELIXIS INC · on record since Feb 12, 2004
Director at Arbutus Biopharma Corp · on record since Dec 31, 2014
Director at ADURO BIOTECH, INC. · on record since Apr 19, 2019
Director at Mountain Crest Acquisition Corp II · on record since Sep 15, 2022

Insider trading activity of KARBE FRANK

Transactions on record: 140; since Feb 17, 2004

Open-market buys: 12; $684.2K

Open-market sells: 16; $1.6M

Companies traded: 7; last filing May 21, 2026

Figures computed from official regulatory filings — methodology.

Companies where KARBE FRANK has traded

Phathom Pharmaceuticals, Inc.11 tx · $353.1K · May 21, 2026
Cidara Therapeutics, Inc.6 tx · $3.3M · Jan 7, 2026
Mountain Crest Acquisition Corp II5 tx · $405.7K · Dec 20, 2023
Myovant Sciences Ltd.55 tx · $1.9M · Jul 9, 2021
ADURO BIOTECH, INC.3 tx · May 28, 2020
Arbutus Biopharma Corp3 tx · Jun 23, 2017
EXELIXIS INC57 tx · $106.5K · Feb 18, 2014

Track record of KARBE FRANK

Statistical track record

Free

Open-market buys: 12

Last buy: Dec 13, 2024

Win rates and median returns are available with a free account (5 insiders/month).

Create a free account

Transaction history of KARBE FRANK

Co-insiders of KARBE FRANK

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Company	Filed	Type	Qty	Price	Value · USD	Src
Phathom Pharmaceuticals, Inc.	May 21, 2026	Award	24,122	0.00 USD	$0	SEC
Cidara Therapeutics, Inc.	Jan 7, 2026	OtherD	-115,000	—	—	SEC
Cidara Therapeutics, Inc.	Jan 7, 2026	Other	-43,125	—	—	SEC
Cidara Therapeutics, Inc.	Jan 7, 2026	Other	-7,526	221.50 USD	$1.7M	SEC
Cidara Therapeutics, Inc.	Dec 12, 2025	Other	-7,290	219.60 USD	$1.6M	SEC
Phathom Pharmaceuticals, Inc.	Jun 5, 2025	Award	10,500	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	Jun 5, 2025	AwardD	17,500	0.00 USD	$0	SEC
Cidara Therapeutics, Inc.	Feb 26, 2025	Award	57,500	0.00 USD	$0	SEC
Cidara Therapeutics, Inc.	Feb 26, 2025	AwardD	115,000	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	Dec 16, 2024	Buy	12,500	7.93 USD	$99.1K	SEC
Phathom Pharmaceuticals, Inc.	May 31, 2024	Award	25,000	10.16 USD	$254K	SEC
Phathom Pharmaceuticals, Inc.	May 24, 2024	AwardD	-17,500	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	May 24, 2024	Award	10,500	0.00 USD	$0	SEC
Mountain Crest Acquisition Corp II	Dec 20, 2023	Award	62,500	0.00 USD	$0	SEC
Mountain Crest Acquisition Corp II	Jul 31, 2023	Buy	137,005	0.73 USD	$100K	SEC
Phathom Pharmaceuticals, Inc.	May 30, 2023	AwardD	15,000	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	May 30, 2023	Award	9,000	0.00 USD	$0	SEC
Mountain Crest Acquisition Corp II	Apr 12, 2023	Buy	242,424	0.83 USD	$201.2K	SEC
Mountain Crest Acquisition Corp II	Sep 15, 2022	Buy	50,000	2.09 USD	$104.5K	SEC
Mountain Crest Acquisition Corp II	Jul 7, 2022	AwardD	472,200	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	May 27, 2022	AwardD	10,000	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	Apr 26, 2022	AwardD	20,000	0.00 USD	$0	SEC
Myovant Sciences Ltd.	Jul 9, 2021	Sell	-3,232	21.75 USD	$70.3K	SEC
Myovant Sciences Ltd.	Apr 19, 2021	AwardD	97,534	0.00 USD	$0	SEC
Myovant Sciences Ltd.	Apr 19, 2021	Award	63,138	0.00 USD	$0	SEC

Company	Filed	Type	Qty	Price	Value · USD	Src
Phathom Pharmaceuticals, Inc.	May 21, 2026	Award	24,122	0.00 USD	$0	SEC
Cidara Therapeutics, Inc.	Jan 7, 2026	OtherD	-115,000	—	—	SEC
Cidara Therapeutics, Inc.	Jan 7, 2026	Other	-43,125	—	—	SEC
Cidara Therapeutics, Inc.	Jan 7, 2026	Other	-7,526	221.50 USD	$1.7M	SEC
Cidara Therapeutics, Inc.	Dec 12, 2025	Other	-7,290	219.60 USD	$1.6M	SEC
Phathom Pharmaceuticals, Inc.	Jun 5, 2025	Award	10,500	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	Jun 5, 2025	AwardD	17,500	0.00 USD	$0	SEC
Cidara Therapeutics, Inc.	Feb 26, 2025	Award	57,500	0.00 USD	$0	SEC
Cidara Therapeutics, Inc.	Feb 26, 2025	AwardD	115,000	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	Dec 16, 2024	Buy	12,500	7.93 USD	$99.1K	SEC
Phathom Pharmaceuticals, Inc.	May 31, 2024	Award	25,000	10.16 USD	$254K	SEC
Phathom Pharmaceuticals, Inc.	May 24, 2024	AwardD	-17,500	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	May 24, 2024	Award	10,500	0.00 USD	$0	SEC
Mountain Crest Acquisition Corp II	Dec 20, 2023	Award	62,500	0.00 USD	$0	SEC
Mountain Crest Acquisition Corp II	Jul 31, 2023	Buy	137,005	0.73 USD	$100K	SEC
Phathom Pharmaceuticals, Inc.	May 30, 2023	AwardD	15,000	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	May 30, 2023	Award	9,000	0.00 USD	$0	SEC
Mountain Crest Acquisition Corp II	Apr 12, 2023	Buy	242,424	0.83 USD	$201.2K	SEC
Mountain Crest Acquisition Corp II	Sep 15, 2022	Buy	50,000	2.09 USD	$104.5K	SEC
Mountain Crest Acquisition Corp II	Jul 7, 2022	AwardD	472,200	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	May 27, 2022	AwardD	10,000	0.00 USD	$0	SEC
Phathom Pharmaceuticals, Inc.	Apr 26, 2022	AwardD	20,000	0.00 USD	$0	SEC
Myovant Sciences Ltd.	Jul 9, 2021	Sell	-3,232	21.75 USD	$70.3K	SEC
Myovant Sciences Ltd.	Apr 19, 2021	AwardD	97,534	0.00 USD	$0	SEC
Myovant Sciences Ltd.	Apr 19, 2021	Award	63,138	0.00 USD	$0	SEC